KRMD
KORU Medical Systems Inc
$
4.150
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.190
Open
4.100
VWAP
4.15
Vol
155.14K
Mkt Cap
191.88M
Low
4.0888
Amount
643.29K
EV/EBITDA(TTM)
--
Total Shares
45.76M
EV
184.08M
EV/OCF(TTM)
--
P/S(TTM)
5.18
KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
9.67M
+18.16%
-0.020
+100%
10.45M
+18.21%
-0.022
+125%
10.99M
+14.09%
-0.018
-12.5%
Estimates Revision
The market is revising No Change the revenue expectations for KORU Medical Systems, Inc. (KRMD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 29.28%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+29.28%
In Past 3 Month
4 Analyst Rating
16.39% Upside
Wall Street analysts forecast KRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is 4.83 USD with a low forecast of 3.50 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
16.39% Upside
Current: 4.150
Low
3.50
Averages
4.83
High
6.00
16.39% Upside
Current: 4.150
Low
3.50
Averages
4.83
High
6.00
Piper Sandler
Neutral
maintain
$4
2025-08-07
Reason
Piper Sandler
Price Target
$4
2025-08-07
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Koru Medical to $4 from $3.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results that beat Street, including revenue of $10.2M/+21% year-over-year as U.S./International grew 15%/34%, respectively. Management also nudged 2025 revenue guidance higher by $1M, reiterated its gross margin percentage outlook, and pointed to positive cash generation in the second half of the year. In general, a solid quarter with upside balanced across the company's three segments, although Piper would still like to see better translation of the strong top-line growth to P&L leverage.
Piper Sandler
Jason Bednar
Neutral
downgrade
2025-05-08
Reason
Piper Sandler
Jason Bednar
Price Target
2025-05-08
downgrade
Neutral
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Koru Medical to $3.50 from $4.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q1 results that beat Street, including revenue of $9.6M/+17.5% year-over-year as U.S./International grew 16%/36%, respectively. The beat was wide enough for management to bump 2025 revenue guidance higher by $0.5M, Piper says, adding that it's encouraging to see gross margin percentage durability despite the geographic mix shift, and management also highlighted plans to submit for approval later this year for two commercialized drugs on the company's Freedom Infusion System.
Piper Sandler
Jason Bednar
Buy
to
Hold
Downgrades
$4.5
2025-02-14
Reason
Piper Sandler
Jason Bednar
Price Target
$4.5
2025-02-14
Downgrades
Buy
to
Hold
Reason
Piper Sandler analyst Jason Bednar downgraded Koru Medical to Neutral from Overweight with an unchanged price target of $4.50. The company's execution "has unquestionably improved," but the stock's valuation is sitting near multi-year highs even off potentially higher revenue numbers, the analyst tells investors in a research note. The firm says Koru's "loftier valuation" is making it "slightly more uneasy about other items," including tougher compares for the U.S. subcutaneous immunoglobulin market, its limited gross margin upside in 2025 and 2026 due to geographic mix, and novel therapies revenue catalysts that look more weighted to 2026 and beyond. As such, Piper believes other stocks offer a superior risk/reward.
Craig-Hallum
Chase Knickerbocker
Strong Buy
Maintains
$5 → $6
2025-01-17
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$5 → $6
2025-01-17
Maintains
Strong Buy
Reason
Lake Street
Frank Takkinen
Strong Buy
Maintains
$4 → $5
2025-01-14
Reason
Lake Street
Frank Takkinen
Price Target
$4 → $5
2025-01-14
Maintains
Strong Buy
Reason
Lake Street raised the firm's price target on Koru Medical to $5 from $4 and keeps a Buy rating on the shares after the company announced preliminary Q4 revenue that beat the firm's and Street's estimates. While the preliminary release provided limited detail into what drove the beat, the firm suspects broad-based business strength given the size of the beat, the analyst tells investors.
Piper Sandler
Jason Bednar
Buy
Maintains
$3 → $3.5
2024-11-14
Reason
Piper Sandler
Jason Bednar
Price Target
$3 → $3.5
2024-11-14
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for KORU Medical Systems Inc (KRMD.O) is -75.80, compared to its 5-year average forward P/E of -0.89. For a more detailed relative valuation and DCF analysis to assess KORU Medical Systems Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.89
Current PE
-75.80
Overvalued PE
101.60
Undervalued PE
-103.38
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
4.20
Current EV/EBITDA
225.00
Overvalued EV/EBITDA
159.54
Undervalued EV/EBITDA
-151.14
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
5.25
Current PS
4.38
Overvalued PS
7.69
Undervalued PS
2.81
Financials
Annual
Quarterly
FY2025Q2
YoY :
+20.93%
10.19M
Total Revenue
FY2025Q2
YoY :
-73.77%
-312.66K
Operating Profit
FY2025Q2
YoY :
-79.08%
-206.87K
Net Income after Tax
FY2025Q2
YoY :
-100.00%
0.00
EPS - Diluted
FY2025Q2
YoY :
+256.62%
-489.15K
Free Cash Flow
FY2025Q2
YoY :
-1.52%
61.47
Gross Profit Margin - %
FY2025Q2
YoY :
+66.30%
-6.02
FCF Margin - %
FY2025Q2
YoY :
-82.69%
-2.03
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
633.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KRMD News & Events
Events Timeline
2025-08-06 (ET)
2025-08-06
17:21:10
KORU Medical raises FY25 revenue view to $39.5M-$40.5M from $38.5M-$39.5M
2025-08-06
17:19:00
KORU Medical reports Q2 adjusted EPS 1c, consensus (2c)
2025-07-07 (ET)
2025-07-07
16:05:40
Koru Medical names Adam Kalbermatten CCO
Sign Up For More Events
Sign Up For More Events
News
9.5
08-06NASDAQ.COMAmerican Well Corporation (AMWL) Reports Q2 Loss, Beats Revenue Estimates
5.0
07-07NewsfilterKORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer
4.5
06-11NewsfilterKORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes
Sign Up For More News
People Also Watch
MOLN
Molecular Partners AG
3.860
USD
+11.24%
EGAN
eGain Corp
5.860
USD
+5.02%
MRCC
Monroe Capital Corp
6.860
USD
+0.96%
BTOC
Armlogi Holding Corp
1.570
USD
+1.29%
FCCO
First Community Corp (South Carolina)
25.880
USD
+2.82%
ELA
Envela Corp
6.550
USD
-2.24%
BRLT
Brilliant Earth Group Inc
2.000
USD
+14.94%
NOTE
FiscalNote Holdings Inc
0.556
USD
0.00%
BIOA
BIOAGE Labs Inc
4.480
USD
+3.23%
NKSH
National Bankshares Inc
29.650
USD
+2.10%
FAQ
What is KORU Medical Systems Inc (KRMD) stock price today?
The current price of KRMD is 4.15 USD — it has increased 2.72 % in the last trading day.
What is KORU Medical Systems Inc (KRMD)'s business?
What is the price predicton of KRMD Stock?
What is KORU Medical Systems Inc (KRMD)'s revenue for the last quarter?
What is KORU Medical Systems Inc (KRMD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for KORU Medical Systems Inc (KRMD)'s fundamentals?
How many employees does KORU Medical Systems Inc (KRMD). have?